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donor bacteremia. We describe a novel mechanism for 
transmission through direct contamination of a thoracic 
vascular graft that was removed at the time of organ 
retrieval. The use of a contaminated innominate artery 
jump graft for pancreas transplantation resulted in 
vascular anastomotic infection in multiple recipients 
from a non-bacteremic donor colonized with Pseudo- 
monas aeruginosa. 
Methods: Patient data was collected by chart review 
from the donor and the kidney, kidney-pancreas, heart, 
lung and liver recipients at 4 separate transplant centers. 
Isolates of P aeruginosa were tested for relatedness by 
molecular typing using pulsed-field gel electrophoresis 
(PFGE). 
Results: The donor was a previously healthy 25 year old 
man who died of a closed head injury. He was intubated 
for 24h prior to organ retrieval. The donor’s routine 
tracheal suction cultures were positive for P aeruginosa 
but all blood cultures were negative. Organs were 
retrieved for lung, liver, kidney-pancreas, kidney, and 
heart transplantation. The donor trachea was transected 
and the intrathoracic organs were removed first. A 
second transplant team retrieved the innominate artery 
graft, which was in close proximity to the open end of 
the donor trachea, and the intra-abdominal organs. The 
kidney-pancreas recipient had Pseudomonas bacteremia 
and rupture of the anastomosis between the innominate 
artery and native iliac artery 48h post-transplant; the 
pancreas was subsequently lost. The renal transplant 
recipient lost his graft from a renal artery anastomotic 
rupture 9 days after transplant. The liver transplant 
recipient died from a ruptured mycotic aneurysm of the 
hepatic artery associated with P aeruginosa bacteremia. 
The lung transplant recipient developed P aeruginosa 
pneumonia but no endovascular infection. The heart 
recipient had an uncomplicated post-operative course. 
All 5 Pseudomonas isolates had the same antibiogram 
and were found to be identical by molecular typing using 
PFGE. 
Conclusion: We conclude that donors may transmit 
bacterial infections to multiple recipients by mech- 
anisms other than donor bacteremia. This highlights the 
importance of obtaining donor cultures from multiple 
sites. In this outbreak, the spillage of tracheal secretions 
from the transected trachea directly contaminated the 
innominate artery graft, which resulted in cross- 
contamination of the intraabdominal organs. Although 
donor tracheal cultures are commonly positive, careful 
consideration should be given to antimicrobial treat- 
ment of recipients when a Gram-negative organism is 
isolated. 
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Aim: To evaluate our strategy of FLU P only in HSCT 
R with non-Candida krusei colonization (COL). 
Materials and Methods: A prospective cohort study 
from July 1996 to December 2001; 289 consecutive 
HSCT R were included to detect Candida spp from oro- 
pharynx and stool (high risk pts) by weekly surveillance 
cultures, taken from the beginning of chemotherapy 
until neutropenia was resolved and were plated onto 
selective Chrom-agar plates. Only the pts with non- 
Ckrusei COL received FLU 200 mg/day until engraft- 
ment or empirical amphotericin B initiation; pts under- 
going antifungal prophylaxis or treatment at the time of 
inclusion were excluded. Demographic characteristics 
were: n pts: 289, mean age: 33.8 (O-70) female: 169 
(58%), hematological diseases: 197 (68%), solid tumors: 
89 (32%) others: 3 (1%) autologous (AU): 203 (70%) 
allogeneic (AL): 86 (30%) mean engraftment days: 12.8 
(3-48). 
Results: There were no differences in the frequency of 
MD IF1 in the compared populations 
l C albicans was the most frequent species isolated in 
COL pts and caused 2 IF1 
l Candida krusei was isolated in 6 (3.4%) COL pts, 3 
selected during FLU P 
l Two Ckrusei caused 2 (1.4%) IF1 and were isolated 
after 9 and 14 days of FLU P 
l There was one mortality related to MD IF1 
Conclusions: (1) There were significantly more 
neutropenia days and empirical amphotericin B usage in 
COL population. (2) FLU P only in non-Candida krusei 
COL pts was safe and cost-effective, avoiding toxicity 
and emergence of resistant strains. 
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We performed a survey to elicit risk factors for CMV 
retinitis (CMVR) after blood stem cell transplantation 
(SCT). A total of 24 cases have been reported from 13 
EBMT centres. In the risk factor analysis, 18 patients 
were included. A control group of 2467 patients was 
selected who were transplanted at the contributing 
centres during the study period who had a follow up 
time of more than one month. The median time from 
transplantation to diagnosis of CMVR was 160 days 
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(range 31-318). The overall probability of developing 
CMVR was 1.07+0.26%. CMVR was more common in 
the patients who had chronic GVHD ((2.08% (p=O.O6)) 
and even higher in patients with extensive chronic 
GVHD ((2.31% (p=O.O5)). In multivariate analysis the 
risk factors for CMVR were having a CMV seronegative 
donor to a CMV seropositive patients, use of peripheral 
blood stem cells, year of SCT later than 1995, and T-cell 
depletion. 
In conclusion, the study supports that CMVR has 
become more common after allogeneic SCT and that 
transferred donor T-cell immunity is an important 
protective factor against CMVR. 
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Vancomycin-resistant Enterococcus faecium (VREF) 
continues to be a problem pathogen, particularly for 
immuncompromised patients such as bone marrow 
transplant patients. Rates of colonization are higher 
than infection, but VREF infections in bone marrow 
transplant patients are associated with high mortality 
despite new options for therapy. Our bone marrow 
transplant units experience a VREF colonization rate of 
12 per cent, or 11.4 cases per 1,000 patient days.This was 
associated with the occurrence of several serious clinical 
infections. Interventions included institution of routine 
surveillance VREF cultures on admission to the unit 
and weekly thereafter to identify VREF cases earlier 
for Contact Precautions, availability of instant antisepsis, 
environmental cultures as epidemiologically indicated 
and re-inservicing of housekeeping staff regarding 
appropriate daily cleaning on the unit, use of a 
germicide with a more acceptable smell for patient 
acceptance, inservicing of unit staff including results of 
pulsed-field gel electrophoresis typing of VREF patient 
and environmental isolates, and rotation of antibiotic 
regimens for empiric therapy of febrile neutropenia 
(piperacillim tazobactam and cefipime rotated every 
three months). Results in two years of follow-up after 
the interventions included a decrease in VREF colon- 
ization prevalence to 6 per cent, or 2 to 5 cases per 
1,000 patient days; clinical VREF infections were 
rare. The routine use of surveillance cultures, enhanced 
antisepsis, improved environmental cleaning, staff 
education regarding VREF strain transmission, and 
antibiotic utilization patterns may be useful in control- 
ling rates of VREF in high-risk immunocompromised 
patients. 
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Invasive fungal infections are a leading cause of 
morbidity and mortality in allogeneic bone marrow 
transplant (BMT) patients both early and late after 
transplant. In this multicenter trial, allogeneic BMT 
patients were randomized to receive long-term anti- 
fungal prophylaxis with either itraconazole (ITRA) (200 
rng IV ql2hrs for 2 days followed by 200 mg IV q24hrs 
or 200 mg oral solution ql2hrs) or fluconazole (FLU) 
(400 mg IV or orally q24hrs.) from day 1 until day 100 
after BMT. Each study drug was given IV for the first 
14 days followed by oral therapy. Patients unable to 
take oral therapy returned to IV study drug. 71 patients 
received ITRA; 67 patients received FLU. Proven 
invasive fungal infections occurred in 6/71 (9%) ITRA 
patients and 17/67 (25%) FLU patients within 180 
days after BMT (P=O.Ol). Proven superficial fungal 
infections occurred in 3/71(4%) ITRA patients and 2/67 
(3%) FLU patients. In a multivariate regression 
analysis using factors known to affect the risk of invasive 
fungal infection after BMT, prophylaxis with ITRA was 
still associated with a lower risk for invasive fungal 
infection (p=O.O2) caused by either yeasts or molds. 
Death from fungal infection occurred in 6/71 (9%) 
ITRA patients and 12167 (18%) FLU patients (p=O.13). 
Both ITRA and FLU were generally well-tolerated. 
Gastrointestinal adverse events (nausea, vomiting, 
diarrhea, abdominal pain) were more frequent in ITRA 
patients (17/71 or 24% vs. 6167 or 9%, p=O.O2). There 
was no appreciable hepatotoxicity with either ITRA or 
FLU. These results suggest that IV/oral ITRA may 
be more effective than IV/oral FLU for long-term 
prophylaxis of early and late invasive fungal infections 
after allogeneic BMT. 
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In the fall of 2001 during a 3-week interval 3 heart 
transplant patients at our hospital were diagnosed with 
nocardia infections. Two patients received their trans- 
plants in 2001 and the third in 1997. All were male 
between 60 and 70 years old. 
